{"analyses":[{"ciLowerLimit":"0.563","ciNumSides":"TWO_SIDED","ciPctValue":"98.457","ciUpperLimit":"0.985","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"95% CI: 0.594 to 0.934","pValue":"0.0106","paramType":"Hazard Ratio (HR)","paramValue":"0.75","statisticalComment":"Stratified by renal function (adequate vs borderline),tumor stage(T2N0vs \\>T2N0), PDL1 status(high vs low/negative)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median OS was not reached due to insufficient number of participants with events 75th percentile OS was not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"41.9","upperLimit":"NA","value":"NA"},{"comment":"Median OS was not reached due to insufficient number of participants with events 75th percentile OS was not reached due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"24.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"533"},{"groupId":"OG001","value":"530"}],"units":"Participants"}],"description":"OS is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e., date of death or censoring - date of randomization + 1)","dispersionType":"Inter-Quartile Range","groups":[{"description":"Durvalumab + Gemcitabine + Cisplatin Treatments and dosing regimens: Durvalumab 1500 mg IV q3w (neoadjuvant) 1500 mg IV q4w (adjuvant post-radical cystectomy) Day 1 and Day 8 (gemcitabine 1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function","id":"OG000","title":"Durvalumab+Gemcitabine+Cisplatin"},{"description":"Treatments and dosing regimens: Day 1 and Day 8 (gemcitabine1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function","id":"OG001","title":"Gemcitabine+Cisplatin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 65 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}